Generic Cancidas Availability

Cancidas is a brand name of caspofungin, approved by the FDA in the following formulation(s):

CANCIDAS (caspofungin acetate - injectable;iv (infusion))

  • Manufacturer: MERCK
    Approval date: January 26, 2001
    Strength(s): 50MG/VIAL [RLD], 70MG/VIAL [RLD]

Has a generic version of Cancidas been approved?

No. There is currently no therapeutically equivalent version of Cancidas available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cancidas. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Aza cyclohexapeptide compounds
    Patent 5,378,804
    Issued: January 3, 1995
    Inventor(s): Balkovec; James M. & Black; Regina M. & Bouffard; Frances A.
    Assignee(s): Merck & Co., Inc.
    Aza cyclohexapeptide compounds are disclosed with a nitrogen attached to the cyclohexapeptide ring at the 5-carbon of the 4-hydroxyornithine component. Such compounds are represented by the formula: ##STR1## The compounds are disclosed as having antifungal, antiprotozoal and anti-Pneumocystis carinii activity.
    Patent expiration dates:
    • September 16, 2013
      ✓ 
      Pediatric exclusivity
  • Aza cyclohexapeptide compounds
    Patent 5,514,650
    Issued: May 7, 1996
    Inventor(s): Balkovec; James M. & Black; Regina M. & Bouffard; Frances A.
    Assignee(s): Merck & Co., Inc.
    Ceretain aza cyclohexapeptide compounds have been found to have superior antibiotic properties. Novel processes for their preparation are also described.
    Patent expiration dates:
    • January 26, 2015
      ✓ 
      Patent use: CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
      ✓ 
      Drug product
    • July 26, 2015
      ✓ 
      Pediatric exclusivity
  • Aza cyclohexapeptide compounds
    Patent 5,792,746
    Issued: August 11, 1998
    Inventor(s): Balkovec; James M. & Bouffard; Frances Aileen & Black; Regina M.
    Assignee(s): Merck & Co., Inc.
    Ceretain aza cyclohexapeptide compounds have been found to have superior antibiotic properties. Novel processes for their preparation are also described.
    Patent expiration dates:
    • September 16, 2013
      ✓ 
      Pediatric exclusivity
  • Antifungal compositions
    Patent 5,952,300
    Issued: September 14, 1999
    Inventor(s): Nerurkar; Maneesh J. & Hunke; William A. & Kaufman; Michael J.
    Assignee(s): Merck & Co., Inc.
    The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of a compound having the formula ##STR1## and the pharmaceutically acceptable salts thereof; b) a pharmaceutically acceptable amount of an excipient such as a bulking agent effective to form a lyophilized cake; and c) a pharmaceutically acceptable amount of acetate buffer effective to provide a pH of between about 4 and 7.
    Patent expiration dates:
    • March 28, 2017
      ✓ 
      Drug product
    • September 28, 2017
      ✓ 
      Pediatric exclusivity
  • Antifungal compositions
    Patent 6,136,783
    Issued: October 24, 2000
    Inventor(s): Neururkar; Maneesh J. & Kaufman; Michael J. & Hunke; William A.
    Assignee(s): Merck & Co., Inc.
    The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of a compound having the formula ##STR1## and the pharmaceutically acceptable salts thereof; b) a pharmaceutically acceptable amount of an excipient such as a bulking agent effective to form a lyophilized cake; and c) a pharmaceutically acceptable amount of acetate buffer effective to provide a pH of between about 4 and 7.
    Patent expiration dates:
    • March 28, 2017
      ✓ 
      Patent use: CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
    • September 28, 2017
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web3)